Intravenous Fosphenytoin in Acute Mania
J Clin Psychiatry 2003;64(4):408-409
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objectives: Since several anticonvulsants are
therapeutic in mania and since acute mania requires rapid and
intensive treatment, we hypothesized that intravenous high-dose
phenytoin might be acutely antimanic. A new prodrug of phenytoin,
fosphenytoin, which has few cardiac or local vein side effects,
was used to test this hypothesis.
Method: Seven patients with a DSM-IV manic
episode and minimal prior drug treatment were given intravenous
fosphenytoin and were assessed at baseline and after 15, 30, 45,
and 60 minutes with the Young Mania Rating Scale, the Clinical
Global Impressions scale, and the Mini-Mental State Examination.
Data were gathered in 2002.
Results: No antimanic effects were observed. No
subject had any clear improvement in manic symptoms on the YMRS
at any timepoint assessed.
Conclusion: Intravenous fosphenytoin at doses
that are effective in status epilepticus appears to be
ineffective in acute mania.